Please provide your email address to receive an email when new articles are posted on . Adding localized radiation therapy to intermittent hormone therapy extended PFS among men with oligometastatic ...

MEDSIR, a leading international oncology research company, has presented the final results of the ZZ‑FIRST study during an ...

A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...

A preclinical study conducted by researchers at UT Southwestern Medical Center reveals that female sex hormones significantly accelerate the course of the rare neurodegenerative eye disease retinitis ...

Female sex hormones can significantly enhance the progression of the rare neurodegenerative eye disease retinitis pigmentosa (RP), according to a preclinical study by researchers at UT Southwestern ...

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival ...

To review the influence of sex hormones on the progression of breast, prostate, gynecologic, and colorectal cancer. The literature was reviewed in an informal manner utilizing the authors' prior ...

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells ...

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintained ...